We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

The Human Alzheimer Disease Project A New Call to Arms

Roger N. Rosenberg, MD1,2; Ronald C. Petersen, PhD, MD3
[+] Author Affiliations
1Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas
2Editor, JAMA Neurology
3Alzheimer’s Disease Research Center, Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota
JAMA Neurol. 2015;72(6):626-628. doi:10.1001/jamaneurol.2015.67.
Text Size: A A A
Published online


The message of this Editorial is simple and straightforward. For the past decade or more, billions of dollars have been invested by the pharmaceutical industry and the National Institutes of Health (NIH) to develop effective therapies for Alzheimer disease. Despite these vast sums of money, an effective therapy to delay or prevent Alzheimer disease has not been developed. Seeing the lack of progress, several major pharmaceutical companies have reduced or eliminated their Alzheimer disease efforts. The result means that without an effective therapy, the number of individuals in the United States who will develop Alzheimer disease in the next 25 years will increase from about 5.5 million to 12 million or more. In a recent analysis of the state of US health from 1990 to 2010, Murray and colleagues1 reported that Alzheimer disease had increased more in rank (from 32 to 9) of years lost to life because of premature mortality compared with any other major disease during this 20-year period. On a worldwide basis, approximately 50 million persons will develop Alzheimer disease by 2050. Further, as we all know, it is not just the individual with Alzheimer disease who is affected but entire families, including spouses, children, and significant others who are mobilized to help the affected individual.

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

2 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Disease-modifying drugs in Alzheimer's disease. Drug Des Devel Ther 2013;7():1471-8.
Neuropathological changes in aging brain. Adv Exp Med Biol 2015;821():11-7.

Care at the Close of Life: Evidence and Experience
Alzheimer Disease: "It's OK, Mama, If You Want to Go, It's OK"

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Supplemental Content